Palvella Therapeutics, Inc. Increase (Decrease) in Operating Capital
Palvella Therapeutics, Inc. (PVLA) reported Increase (Decrease) in Operating Capital of -$89.00 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingCapital · last filed 2024-11-13
- Palvella Therapeutics, Inc. increase (decrease) in operating capital for the quarter ending 2024-09-30 was -$1.86M, a 111.99% decline year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in operating capital for the quarter ending 2024-06-30 was -$2.19M, a 111.60% decline year-over-year.
- Palvella Therapeutics, Inc. increase (decrease) in operating capital for the quarter ending 2024-03-31 was $3.96M.
- Palvella Therapeutics, Inc. increase (decrease) in operating capital for the quarter ending 2023-09-30 was $15.52M, a 3341.02% increase year-over-year.
| Period end | Increase (Decrease) in Operating Capital 3 month | Increase (Decrease) in Operating Capital 6 month | Increase (Decrease) in Operating Capital 6 month as first filed | Increase (Decrease) in Operating Capital 9 month | Increase (Decrease) in Operating Capital 9 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$4.05M derived: sum of 2 quarters · filed 2024-11-13 | -$89.00K 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | -$2.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $1.77M 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $3.96M 10-Q · filed 2024-05-15 | ||||
| 2023-09-30 | $15.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $34.41M derived: sum of 2 quarters · filed 2024-11-13 | $33.80M 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $18.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $18.29M 10-Q · filed 2024-08-14 | |||
| 2023-03-31 | -$607.00K 10-Q · filed 2024-05-15 | ||||
| 2022-09-30 | $451.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $7.74M derived: sum of 2 quarters · filed 2023-11-14 | $27.39M 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $7.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $26.94M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $19.65M 10-Q · filed 2023-05-11 | ||||
| 2021-09-30 | -$56.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | -$43.51M derived: sum of 2 quarters · filed 2022-11-04 | -$33.79M 10-Q · filed 2022-11-04 | ||
| 2021-06-30 | -$43.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$33.73M 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $9.72M 10-Q · filed 2022-05-11 | ||||
| 2020-09-30 | -$5.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $1.34M derived: sum of 2 quarters · filed 2021-11-02 | $14.79M 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | $6.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $20.25M 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $13.46M 10-Q · filed 2021-05-17 | ||||
| 2019-09-30 | $12.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $12.91M derived: sum of 2 quarters · filed 2020-11-04 | $18.83M 10-Q · filed 2020-11-04 | $19.36M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $831.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $6.75M 10-Q · filed 2020-08-10 | $7.12M 10-Q · filed 2019-08-09 | ||
| 2019-03-31 | $5.92M 10-Q · filed 2020-05-11 | ||||
| 2018-09-30 | $9.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $19.54M derived: sum of 2 quarters · filed 2019-11-12 | -$19.37M 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $10.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | -$28.58M 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | -$38.91M 10-Q · filed 2019-05-10 | ||||
| 2017-09-30 | -$41.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$44.36M derived: sum of 2 quarters · filed 2018-11-07 | -$77.27M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$35.78M 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | -$32.91M 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |